Blog / glp 1
What Orforglipron Research Shows About Oral GLP-1 Pills and What to Track
A plain guide to the ATTAIN-1 and ACHIEVE-1 orforglipron trials, how a daily GLP-1 pill differs from injectables, and what to record.
By Peppy Team6 min read
Most GLP-1 medicines people talk about are injections. Semaglutide and tirzepatide pens get the headlines, and a weekly shot is what many people picture when they hear "GLP-1." Orforglipron is different. It is a once-daily pill, and it is not a peptide at all.
This post walks through what the main orforglipron research reports, how it differs from the injectable GLP-1 options, and what is worth writing down if your provider has you on it. As always, whether any medicine fits you is a decision for your licensed healthcare provider. The goal here is to help you understand the research and keep a clean record.
What orforglipron is
Orforglipron is a GLP-1 receptor agonist. That means it acts on the same receptor as semaglutide, liraglutide and the GLP-1 part of tirzepatide.
The big difference is its structure. Semaglutide and tirzepatide are peptides, which are chains of amino acids. Peptides are usually broken down in the gut, which is one reason most of them are injected. Orforglipron is a small molecule. The researchers behind the main trials describe it as a "small-molecule, nonpeptide oral" GLP-1 receptor agonist. In plain terms, it was designed to be taken by mouth as a regular pill.
According to a 2026 review in the journal Drugs titled Orforglipron: First Approval, orforglipron (brand name Foundayo) received its first approval in the USA in April 2026. That approval covers long-term weight management in adults with obesity, or adults with overweight and at least one weight-related condition, alongside a reduced-calorie diet and more physical activity. The same review notes it was under regulatory review for type 2 diabetes in other regions and in phase 3 trials for several other conditions.
What the ATTAIN-1 trial reported
The main obesity trial is ATTAIN-1, published in the New England Journal of Medicine in 2025 (Wharton and colleagues). Here is what the paper reports.
The setup
- 3,127 adults with obesity and without diabetes took part.
- People were randomly assigned to one of three orforglipron dose levels or a placebo, taken once daily.
- Everyone was also asked to follow a healthy diet and stay active.
- The trial ran for 72 weeks, and the main measure was the percent change in body weight.
The results
- Average weight change at 72 weeks ranged from about 7.5% to 11.2% across the orforglipron groups, compared with 2.1% on placebo.
- In the highest dose group studied, 54.6% of people lost 10% or more of their body weight, compared with 12.9% on placebo.
- Waist size, systolic blood pressure, triglycerides and non-HDL cholesterol also improved compared with placebo.
Side effects in the trial
The authors report that the most common side effects were gastrointestinal, mostly mild to moderate. Between 5.3% and 10.3% of people in the orforglipron groups stopped treatment because of side effects, compared with 2.7% on placebo. The authors describe this pattern as consistent with other GLP-1 medicines.
These are group averages from one trial population. Individual results vary a lot, and your provider is the one who can judge what applies to you.
What the ACHIEVE-1 trial reported
Orforglipron was also tested in people with type 2 diabetes. The ACHIEVE-1 trial, also published in the New England Journal of Medicine in 2025 (Rosenstock and colleagues), included 559 adults with early type 2 diabetes who were managing it with diet and exercise only.
According to the paper:
- The main measure was the change in HbA1c, a blood test that reflects average blood sugar over about three months.
- Average HbA1c started at 8.0%. After 40 weeks it was 6.5% to 6.7% in the orforglipron groups.
- Average weight change was 4.5% to 7.6% across the orforglipron groups, compared with 1.7% on placebo.
- Most side effects were mild to moderate gastrointestinal events, and the authors note that most happened during the dose increase period.
- No episodes of severe low blood sugar were reported.
How an oral GLP-1 compares with injectables
It is easy to frame this as "pill versus shot," but the research is not a head-to-head contest here. ATTAIN-1 and ACHIEVE-1 compared orforglipron with placebo, not with semaglutide or tirzepatide. So these trials do not tell you which option works better for any one person.
What does differ is the daily routine:
- Frequency. Orforglipron in these trials was once daily. Semaglutide and tirzepatide injections are commonly given once weekly.
- Format. A pill means no syringe, pen or injection site. An injection means tracking sites and, for some people, vials and syringe units.
- Habit shape. A daily pill can be easier to fold into a morning routine, but a daily habit also gives more chances to miss one.
If you want to read about the other oral GLP-1 option that is a peptide, our post on oral vs injectable semaglutide covers that research. For the comparison itself, the right questions go to your provider, who can weigh your history, other medicines and goals.
What to track if you take a daily GLP-1 pill
A daily medicine creates a lot of small data points. Kept well, they make your appointments much more useful. Here is a simple list of what is worth recording.
The dose and the time
Write down the dose your provider gave you and the time you took it each day. If your provider steps the dose up over time, record each change and the date it happened. Over a few months, that log answers the question every provider asks: "How has it been going since we changed the dose?"
Missed or late doses
Daily medicines get missed. Note when it happens, without judgment. Do not guess at catching up. Check the label or ask your provider what to do after a missed dose, and record what you did.
Side effects next to the dose
The trials above report gastrointestinal effects as the most common, often around dose increases. A quick daily check-in (none, mild, moderate, severe) next to your dose log makes patterns easy to see. Bring the record to your provider rather than interpreting it yourself.
Weight and other numbers
Weekly weigh-ins at a consistent time are easier to read than daily ones. If your provider is tracking HbA1c, blood pressure or waist size, write those down with the date too.
Other medicines
Note any other medicines or supplements you take and when they change. Your provider and pharmacist will want this full picture.
Keeping a record in Peppy
Peppy is a GLP-1 tracker app for iPhone, and it works for a daily routine as well as a weekly one. You can add a custom entry for a medicine that is not in the library, set dose reminders for each dose, and see every logged, late or missed dose in your dose history. Weight sits on a chart next to your doses through weight tracking, and side effect check-ins are covered in the weight, side effects and history guide.
If you are moving from an injectable to a pill, or use both a pill and an injectable your provider prescribed, the GLP-1 tracker page shows how the records sit together. For the injectable side, the free peptide calculator turns your vial strength, the water added and the dose your provider gave you into units on the syringe. It only works out the numbers you enter and never suggests a dose.
There is no account to create, and your records stay on your iPhone and your own iCloud backup.
Key takeaways
- Orforglipron is a once-daily oral GLP-1 receptor agonist that is a small molecule, not a peptide.
- In ATTAIN-1, average weight loss over 72 weeks was meaningfully greater than placebo, with mostly mild to moderate gastrointestinal side effects.
- In ACHIEVE-1, people with early type 2 diabetes saw lower HbA1c than placebo over 40 weeks.
- These trials compared orforglipron with placebo, not with injectable GLP-1 medicines.
- A clear daily record of doses, missed doses, side effects and weight gives your provider the best picture to work from.
More from the blog

semaglutide6 min read
Semaglutide Benefits: What the Evidence Says and How to Track Your Progress
A plain guide to semaglutide benefits backed by FDA approvals and research, what they do not promise, and how to track your own progress with your provider.
- semaglutide
- glp 1
- weight

semaglutide6 min read
Semaglutide Tracker: How to Log Doses, Weight and Side Effects Week by Week
A practical semaglutide tracker guide: what to log at every weekly shot, how to track weight and side effects, and what to bring to your provider.
- semaglutide
- glp 1
- dose log

semaglutide6 min read
CagriSema Research Explained: What the REDEFINE Trials Show and What to Track
A plain guide to CagriSema research: what the REDEFINE trials reported, what is still unknown, and what to track in a peptide tracker.
- semaglutide
- glp 1
- tracking
